FORWARD 1: A Randomized Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer Primary
Brief description of study
If you have been diagnosed with advanced epithelial ovarian cancer (EOC), peritoneal cancer or fallopian tube cancer, you may qualify to participate in a study evaluating an investigation drug, Mirvetuximab soravtansine (IMGN853) versus chemotherapy to treat your cancer. The main goal of the phase III, trial is to compare the effects of Mirvetuximab sorvtansine versus the effects of chemotherapy for the treatment of ovarian cancer, peritoneal cancer, or fallopian tube cancer to find out, which is better. This study will also evaluate how safe this drug reacts to you and your disease.
Clinical Study Identifier: s15-00678
ClinicalTrials.gov Identifier: NCTs15-00678
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
